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Fibrosis blood tests are usually developed using significant fibrosis, which is a unique
diagnostic target; however, these tests are employed for other diagnostic targets,
such as cirrhosis. We aimed to improve fibrosis staging accuracy by simultaneously
targeting biomarkers for several diagnostic targets. A total of 3,809 patients were
included, comprising 1,012 individuals with chronic hepatitis C (CHC) into a
derivation population and 2,797 individuals into validation populations of different
etiologies (CHC, chronic hepatitis B, human immunodeficiency virus/CHC,
nonalcoholic fatty liver disease, alcohol) using Metavir fibrosis stages as reference.
FibroMeter biomarkers were targeted for different fibrosis-stage combinations into
classical scores by logistic regression. Independent scores were combined into a
single score reflecting Metavir stages by linear regression and called Multi-
FibroMeter Version Second Generation (V2G). The primary objective was to combine
the advantages of a test targeted for significant fibrosis (FibroMeter) with those of a
test targeted for cirrhosis (CirrhoMeter). In the derivation CHC population, we first
compared Multi-FibroMeter to FibroMeter and observed significant increases in the
cirrhosis area under the receiver operating characteristic curve (AUROC),
Obuchowski index (reflecting all fibrosis-stage AUROCs), and classification metric
(six classes expressed as a correctly classified percentage) and a nonsignificant
increase in significant fibrosis AUROC. Thereafter, we compared it to CirroMeter and
observed a nonsignificant increase in the cirrhosis AUROC. In all 3,809 patients,
respective accuracies for Multi-FibroMeter and FibroMeter were the following:
cirrhosis AUROC, 0.906 versus 0.878 ( 0.001; versus CirroMeter, 0.897, 0.014);
Obuchowski index, 0.795 versus 0.791 ( 0.059); classification, 86.0% versus 82.1% (
0.001); significant fibrosis AUROC, 0.833 versus 0.832 ( 0.366). Multi-FibroMeter
had the highest correlation with the area of portoseptal fibrosis and the highest
reproducibility over time. Correct classification rates of Multi-FibroMeter with
hyaluronate (V2G, 86.0%) or without (V3G, 86.1%) did not differ ( 0.938).
Multitargeting biomarkers significantly improves fibrosis staging and especially
cirrhosis diagnosis compared to classical single-targeted blood tests. (
2018;2:455-466).
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